

TABLE OF CONTENTS

FOREWORD	xi
PREFACE	xiii
CONTRIBUTORS	xv
REVIEWERS	xxi
SECTION I—MAGNITUDE/SIGNIFICANCE OF DRUG-INDUCED DISEASES: IMPACT ON THE HEALTHCARE SYSTEM	1
Chapter 1: Drug Safety and Drug-Induced Diseases: The Regulatory, Legal, and Practice Environments	3
<i>Cynthia Reilly, MS, BS Pharm</i>	
Chapter 2: Epidemiology and Public Health Impact of Drug-Induced Diseases	19
<i>John R. Litaker, PhD, MSc, MMedSc, and James P. Wilson, PharmD, PhD, FASHP</i>	
Chapter 3: Factors Contributing to Drug-Induced Diseases	31
<i>Tyler Shugg, PharmD, Abdullah Assiri, PharmD, and Brian R. Overholser, PharmD</i>	
Chapter 4: Postmarketing Surveillance for Drug-Induced Diseases	47
<i>Tobias Peschel, MD, PhD, MBA, and Hugh H. Tilson, MD, DrPH</i>	
Chapter 5: Evaluating Patients for Drug-Induced Diseases	59
<i>Douglas A. Miller, PharmD, and James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA</i>	
SECTION II—DRUG-INDUCED DERMATOLOGIC DISEASES	69
Chapter 6: Drug Allergy and Cutaneous Diseases	71
<i>Lynne M. Sylvia, PharmD</i>	
Chapter 7: Systemic Lupus Erythematosus-Like Syndrome	123
<i>Karen W. Lee, PharmD, BCPS, and Matthew F. Ambury, PharmD, BCPS</i>	
Chapter 8: Photosensitivity	143
<i>Julie M. Koehler, PharmD, FCCP</i>	
Chapter 9: Alopecia, Hirsutism, and Hypertrichosis	165
<i>Kristine E. Keplar, PharmD</i>	
SECTION III—DRUG-INDUCED NEUROLOGICAL DISEASES	215
Chapter 10: Seizures	217
<i>Timothy E. Welty, PharmD, FCCP, BCPS</i>	
Chapter 11: Stroke	229
<i>Denise H. Rhoney, PharmD, FCCP, FCCM, FNCS</i>	

TABLE OF CONTENTS

Chapter 12: Movement Disorders	253
<i>Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP; Khashayar Dashtipour, MD, PhD; and David M. Swope, MD</i>	
Chapter 13: Peripheral Neuropathy	279
<i>Dennis Parker, Jr., PharmD</i>	
Chapter 14: Visual Disturbances	295
<i>Yaman Kaakeh, PharmD, BCPS, BCNSP, CNSC, and Steven R. Abel, PharmD, FASHP</i>	
Chapter 15: Delirium	325
<i>Matthew A. Fuller, PharmD, FASHP, BCPP</i>	
Chapter 16: Sleep Disorders	347
<i>Lisa L. Forsyth, PharmD, FCCM</i>	
Chapter 17: Cognitive Disorders	357
<i>Michele Y. Splinter, PharmD, MS, BCPS, FCCP</i>	
SECTION IV—DRUG-INDUCED PSYCHIATRIC DISEASES	373
Chapter 18: Depression	375
<i>Sheila Botts, PharmD, FCCP, BCPP, and Melody Ryan, PharmD, MPH</i>	
Chapter 19: Anxiety	399
<i>Julie A. Dopheide, PharmD, BCPP, FASHP, and Seth Gomez, PharmD, BCPP</i>	
Chapter 20: Psychosis	415
<i>Jessica L. Gören, PharmD, BCPP</i>	
SECTION V—DRUG-INDUCED PULMONARY DISEASES	429
Chapter 21: Interstitial Lung Disease/Pulmonary Fibrosis	431
<i>Jordan R. Covvey, PharmD, PhD, BCPS, and Erin E. Mancl, PharmD, BCPS, BCCCP</i>	
Chapter 22: Asthma and Bronchospasm	451
<i>Suzanne G. Bollmeier, PharmD, BCPS, AE-C, and Rebecca L. Stauffer, PharmD, BCPS</i>	
SECTION VI—DRUG-INDUCED CARDIOVASCULAR DISEASES	469
Chapter 23: Myocardial Ischemia and Acute Coronary Syndromes	471
<i>Kevin M. Sowinski, PharmD, FCCP</i>	
Chapter 24: Heart Failure	501
<i>Yazid N. Al Hamarneh BSc(Pharm), PhD, and Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS</i>	
Chapter 25: Ventricular Arrhythmias	523
<i>James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA</i>	
Chapter 26: Supraventricular Arrhythmias	569
<i>James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA</i>	

TABLE OF CONTENTS

Chapter 27: Hypertension	617
<i>Liza W. Claus, PharmD, BCACP, and Joseph J. Saseen, PharmD, BCPS, BCACP, FCCP, FASHP</i>	
Chapter 28: Hypotension	631
<i>Katy E. Trinkley, PharmD, BCACP, and Robert L. Page II, PharmD, MSPH, BCPS (AQ-Cardiology), BCGP, FCCP, FAHA, FASHP, FHFSA</i>	
Chapter 29: Valvular and Pericardial Heart Disease	659
<i>Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACCC, BCPS (AQ-Cardiology), and Frank E. Silvestry, MD, FACC, FASE</i>	
SECTION VII—DRUG-INDUCED ENDOCRINE DISEASES	677
Chapter 30: Glucose and Insulin Dysregulation	679
<i>Devra K. Dang, PharmD, BCPS, CDE, FNAP; Frank Pucino, Jr., PharmD, MPH, FASHP, FCCP; Charles D. Ponte, PharmD, BC-ADM, BCPS, CDE, CPE, FAADE, FAPhA, FASHP, FCCP, FNAP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP</i>	
Chapter 31: Thyroid Diseases	697
<i>Genevieve Lynn Ness, PharmD; Judy T. Chen, PharmD, BCPS, BCACP, CDE, FNAP; Betty J. Dong, PharmD, FASHP, FAPhA, FCCP; Frank Pucino, Jr., PharmD, MPH, FASHP, FCCP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP</i>	
Chapter 32: Hypothalamic, Pituitary, and Adrenal Diseases	729
<i>Andrew Y. Hwang, PharmD, BCPS; Steven M. Smith, PharmD, MPH, BCPS; and John G. Gums, PharmD, FCCP</i>	
Chapter 33: Sexual Dysfunction in Males	757
<i>Mary Lee, PharmD, BCPS, FCCP, and Roohollah Sharifi, MD, FACS</i>	
Chapter 34: Gynecologic Diseases and Infertility in Women	781
<i>Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP</i>	
SECTION VIII—DRUG-INDUCED GASTROINTESTINAL DISEASES	807
Chapter 35: Upper Gastrointestinal Ulceration	809
<i>Dianne W. May, PharmD, FCCP, BCPS; Micaela Carroll, PharmD, BCPS; and J. Russell May, PharmD, FASHP</i>	
Chapter 36: Diarrhea	821
<i>Sarah A. Nisly, PharmD, BCPS, FCCP, and Alison M. Walton, PharmD, BCPS</i>	
Chapter 37: Constipation	835
<i>Sarah A. Nisly, PharmD, BCPS, FCCP, and Carolyn M. Jung, PharmD, BCPS</i>	
Chapter 38: Hepatic and Cholestatic Diseases	845
<i>Scott S. Malinowski, PharmD, and Daniel M. Riche, PharmD, FCCP, BCPS, CDE, ASH-CHC, CLS</i>	
Chapter 39: Pancreatitis	877
<i>Pramodini B. Kale-Pradhan, PharmD, and Sheila M. Wilhelm, PharmD, FCCP, BCPS</i>	

TABLE OF CONTENTS

Chapter 40: Nausea and Vomiting	905
<i>Saeed K. Alzghari, MS, MBA (HOM), PharmD, BCPS; Bonnie A. Labdi, PharmD, BCOP; and Jon D. Herrington, PharmD, BCPS, BCOP</i>	
SECTION IX—DRUG-INDUCED DISEASES OF THE KIDNEY AND FLUID & ELECTROLYTE DISORDERS	939
Chapter 41: Acute Kidney Injury	941
<i>Amy Barton Pai, PharmD, BCPS, FASN, FCCP, FNKF, and Nicole M. Wegrzyn, PharmD, BCACP</i>	
Chapter 42: Chronic Kidney Disease	965
<i>Mary K. Stamatakis, PharmD</i>	
Chapter 43: Syndrome of Inappropriate Antidiuretic Hormone Secretion and Diabetes Insipidus	981
<i>Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS, and Daniel E. Hilleman, PharmD, FCCP</i>	
Chapter 44: Acid–Base Disorders	1001
<i>Lori D. Wazny, BSc(Pharm), PharmD, EPPh; J. Christine Davis, BSc(Pharm), PharmD, ACPR; and Robert E. Ariano, PharmD, BCPS, FCCM</i>	
SECTION X—DRUG-INDUCED HEMATOLOGICAL DISORDERS	1023
Chapter 45: Bleeding Disorders	1025
<i>Tiffany Pon, PharmD, BCPS, and Jaekyu Shin, PharmD, MS, BCPS</i>	
Chapter 46: Thrombocytopenia	1049
<i>Kellie Jones Weddle, PharmD, BCOP, FCCP, FHOPA, and Patrick J. Kiel, PharmD, BCPS, BCOP</i>	
Chapter 47: Thromboembolic Diseases	1063
<i>Candice L. Garwood, PharmD, FCCP, BCPS, BCACP</i>	
Chapter 48: Neutropenia and Agranulocytosis	1087
<i>Teresa C. Thakrar, PharmD, BCOP, and Christopher A. Fausel, PharmD, MHA, BCOP</i>	
Chapter 49: Anemias	1099
<i>LeAnn B. Norris, PharmD, BCPS, BCOP, and Charles L. Bennett, MD, PhD, MPP</i>	
SECTION XI—DRUG-INDUCED BONE, JOINT, AND MUSCLE DISEASES	1117
Chapter 50: Osteoporosis and Osteomalacia	1119
<i>Laura M. Borgelt, PharmD, FCCP, BCPS, and Danielle R. Fixen, PharmD</i>	
Chapter 51: Gout and Hyperuricemia	1135
<i>Jasmine D. Gonzalvo, PharmD, BCPS, BC-ADM, CDE, LDE</i>	
Chapter 52: Myopathy	1149
<i>Craig Williams, PharmD, FLNA, BCPS</i>	

TABLE OF CONTENTS

SECTION XII—MISCELLANEOUS DRUG-INDUCED DISEASES	1163
Chapter 53: Weight Gain	1165
<i>Amy Heck Sheehan, PharmD</i>	
Chapter 54: Temperature Dysregulation	1185
<i>Susan M. Wilson, PharmD, and Ian A. Ross, PharmD</i>	
Chapter 55: Ototoxicity	1233
<i>Monica L. Miller, PharmD, MS</i>	
Chapter 56: Oral Manifestations of Systemically Administered Drugs	1253
<i>Ashley H. Meredith, PharmD, BCACP, BCPS, CDE</i>	
Chapter 57: Neoplastic Diseases	1283
<i>Sandra Cuellar, PharmD, BCOP, and Christina Mactal Haaf, PharmD, BCOP, BCPS</i>	
Chapter 58: Teratogenicity	1311
<i>Kylie N. Barnes, PharmD, BCPS</i>	
INDEX	1343